Scientific publications

Oral versus intravenous therapy in the treatment of systemic mycosis

Mar 1, 2004 | Magazine: Clinical Microbiologic and Infection

Perea JR, Díaz De Rada BS, Quetglas EG, Juarez MJ.
Servicio de Farmacología Clínica, Clínica Universitaria, Universidad de Navarra, Avenida Pío XII sn Pamplona 31008, Spain.


The great majority of systemic fungal infections require long-term therapy that often extends 6-12 months, particularly in immunosuppressed patients. It can be difficult to comply with this requirement when the drug to be used is only available for intravenous administration, because problems related to maintaining a permeable venous pathway for long periods arise. The availability of an intravenously (IV) and orally (PO) administered drug can solve this problem by making sequential therapy possible.

Voriconazole is a new antifungal agent that, apart from satisfying this requirement because it has a high oral bioavailability, presents a broad spectrum of antifungal activity that makes its use possible, a priori, in the initial and/or sequential IV/PO treatment of any systemic mycotic infection.

Based on current costs there is potential for savings compared with liposomal amphotericin B.

CITATION  Clin Microbiol Infect. 2004 Mar;10 Suppl 1:96-106